Targeting the JAK/STAT3 pathway with Ruxolitinib in a mouse model of recessive dystrophic epidermolysis bullosa-squamous cell carcinoma.
2020
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
14
References
4
Citations
NaN
KQI